Document Detail


Treatment of deep vein thrombosis: is thrombosis regression a desirable endpoint?
MedLine Citation:
PMID:  9200344     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Recent studies on the treatment of acute deep vein thrombosis (DVT) with low-molecular-weight heparins have demonstrated that a certain degree of early recanalization of thrombosed veins can be obtained which is higher than that observed under standard heparin treatment. Thrombolytic treatment of DVT is mainly advocated because a reduction of late sequelae of DVT is expected from early thrombolysis. It has been made likely by several small long-term studies that this expectation is true, but conclusive evidence is still missing. There are also large differences in the reported incidence of late postthrombotic syndrome after acute DVT. It seems likely that there is a minimal reopening rate which is required to be of possible clinical value to the individual patient. A 30% or higher reduction of the Marder score is at present used in several clinical trials as a sign of individual response to the treatment and may prove to be a useful clinical endpoint in these and in future studies. Validated methods to predict the late sequelae of acute DVT, mainly severe postthrombotic syndrome, do not yet exist. Foot plethysmography, air plethysmography, duplex sonography (peak velocity of venous reflux, valve competence), and venous pressure reduction under exercise are possible candidates to be used in future prospective trials. From the existing evidence it is very likely that a marked or total reduction of thrombi will reduce the incidence of postthrombotic syndromes. Clinical studies aiming at a high rate of venous recanalization by prolonged treatment with low-molecular-weight heparins are ongoing.
Authors:
H K Breddin
Related Documents :
2545054 - Prevention of postoperative deep vein thrombosis by one daily injection of low molecula...
7858334 - Heparin coated percutaneous cardiopulmonary support for the treatment of circulatory co...
8128454 - Clinical evaluation of low-molecular-weight heparin (fr-860) on disseminated intravascu...
1966794 - Levels of thrombin--antithrombin-iii complex and factor viii activity in relation to po...
9765034 - Radiation protection of the ovaries in young scoliosis patients.
9129064 - Evaluation of pharmacokinetics, safety, tolerance, and activity of combination of zalci...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Seminars in thrombosis and hemostasis     Volume:  23     ISSN:  0094-6176     ISO Abbreviation:  Semin. Thromb. Hemost.     Publication Date:  1997  
Date Detail:
Created Date:  1997-08-05     Completed Date:  1997-08-05     Revised Date:  2006-03-07    
Medline Journal Info:
Nlm Unique ID:  0431155     Medline TA:  Semin Thromb Hemost     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  179-83     Citation Subset:  IM    
Affiliation:
International Institute of Thrombosis and Vascular Diseases, Frankfurt am Main, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Heparin, Low-Molecular-Weight / therapeutic use
Humans
Postphlebitic Syndrome / drug therapy
Thrombophlebitis / drug therapy*
Chemical
Reg. No./Substance:
0/Heparin, Low-Molecular-Weight

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Low-molecular-weight heparin therapy and mortality.
Next Document:  The natural history of deep-vein thrombosis.